ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have earned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $107.3333.

Several analysts have issued reports on ANIP shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, June 1st. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, VP Meredith Cook sold 500 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $78.16, for a total value of $39,080.00. Following the completion of the sale, the vice president owned 78,390 shares of the company’s stock, valued at $6,126,962.40. This represents a 0.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Thomas Andrew Rowland sold 459 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $79.21, for a total value of $36,357.39. Following the completion of the sale, the senior vice president directly owned 38,271 shares of the company’s stock, valued at approximately $3,031,445.91. This represents a 1.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 78,516 shares of company stock valued at $6,154,976 over the last 90 days. Company insiders own 8.10% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Divisadero Street Capital Management LP purchased a new stake in ANI Pharmaceuticals in the third quarter worth $21,454,000. Apis Capital Advisors LLC lifted its stake in ANI Pharmaceuticals by 28.1% in the third quarter. Apis Capital Advisors LLC now owns 164,000 shares of the specialty pharmaceutical company’s stock worth $15,022,000 after acquiring an additional 36,000 shares during the period. Oliver Luxxe Assets LLC purchased a new stake in ANI Pharmaceuticals in the fourth quarter worth $1,823,000. Vanguard Group Inc. lifted its stake in ANI Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after acquiring an additional 27,598 shares during the period. Finally, Artemis Investment Management LLP purchased a new stake in ANI Pharmaceuticals in the fourth quarter worth $1,706,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Down 0.2%

ANIP stock opened at $81.65 on Friday. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06. The company’s 50 day moving average is $79.60 and its 200 day moving average is $79.41. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of 20.67 and a beta of 0.44. ANI Pharmaceuticals has a 1-year low of $61.17 and a 1-year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.77. The company had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. ANI Pharmaceuticals’s revenue for the quarter was up 20.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts predict that ANI Pharmaceuticals will post 8.07 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.